CASI Pharmaceuticals (CASIF) Gross Profit (2022 - 2025)

CASI Pharmaceuticals (CASIF) has 4 years of Gross Profit data on file, last reported at $3.7 million in Q4 2025.

• Quarterly Gross Profit rose 14.41% year-over-year to $3.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.1 million (down 9.6% YoY) and the FY2025 annual result came in at $10.1 million, down 9.6% from the prior year.
• Gross Profit advanced to $3.7 million in Q4 2025, from $706000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $11.0 million in Q4 2022 to a low of $706000.0 in Q3 2025.
• A 4-year average of $4.3 million and a median of $4.1 million in 2023 frame the typical range for Gross Profit.
• The widest YoY moves for Gross Profit: up 100.39% in 2025, down 82.55% in 2025.
• Tracing CASIF's Gross Profit over 4 years: stood at $11.0 million in 2022, then tumbled by 63.06% to $4.1 million in 2023, then slipped by 20.47% to $3.2 million in 2024, then rose by 14.41% to $3.7 million in 2025.
• The last three Gross Profit figures came in at $3.7 million (Q4 2025), $706000.0 (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.